Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Update

Co-Diagnostics, Inc. (NASDAQ:CODX) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 208,700 shares, a decrease of 7.8% from the October 15th total of 226,400 shares. Based on an average trading volume of 246,900 shares, the days-to-cover ratio is currently 0.8 days.

Co-Diagnostics Stock Down 0.9 %

Co-Diagnostics stock opened at $1.07 on Wednesday. Co-Diagnostics has a twelve month low of $1.00 and a twelve month high of $2.23. The business has a fifty day moving average of $1.23 and a two-hundred day moving average of $1.25. The firm has a market cap of $34.17 million, a P/E ratio of -0.78 and a beta of -0.84.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and set a $1.50 target price on shares of Co-Diagnostics in a research note on Monday, November 11th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Co-Diagnostics stock. Jane Street Group LLC acquired a new position in Co-Diagnostics, Inc. (NASDAQ:CODX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 44,124 shares of the company’s stock, valued at approximately $55,000. Jane Street Group LLC owned 0.14% of Co-Diagnostics at the end of the most recent reporting period. 14.99% of the stock is owned by institutional investors.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.